Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

54.02
Delayed Data
As of Apr 26
 +2.67 / +5.20%
Today’s Change
31.38
Today|||52-Week Range
80.11
+44.28%
Year-to-Date
No recent news for Alnylam Pharmaceuticals Inc.

Today’s Trading

Previous close51.35
Today’s open51.55
Day’s range51.54 - 54.31
Volume808,194
Average volume (3 months)963,548
Market cap$4.6B
Dividend yield--
Data as of 04/26/2017

Growth & Valuation

Earnings growth (last year)-38.84%
Earnings growth (this year)-7.98%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+14.75%
P/E ratioNM
Price/Sales67.96
Price/Book5.05

Competitors

 Today’s
change
Today’s
% change
MNKMallinckrodt Plc+0.28+0.61%
TAROTaro Pharmaceutical ...+3.69+3.23%
OPKOPKO Health Inc0.000.00%
AGNPRAAllergan plc+2.32+0.27%
Data as of 04/26/2017

Financials

Next reporting dateMay 11, 2017
EPS forecast (this quarter)-$1.27
Annual revenue (last year)$47.2M
Annual profit (last year)-$410.1M
Net profit margin-869.63%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs